BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ --
China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a
leading China-based advanced
in-vitro diagnostic ("IVD") company, today announced that it has
received approval for its real-time PCR-based Epidermal Growth
Factor Receptor ("EGFR") Assay (the "EGFR PCR Assay") for the use
of lung cancer targeted drugs from the State Food and Drug
Administration of China (the
"SFDA").
The EGFR PCR Assay is used for the detection of the 28 most
common somatic mutations in the EGFR gene of patients with
non-small cell lung cancer ("NSCLC") and provides a qualitative
assessment of mutation status to determine the use of lung cancer
targeted drugs for patients.
With its own internal research and development efforts, the
Company has successfully developed its first PCR-based assay
related to companion diagnostic tests for personalized medicines
for cancer patients. The Company's EGFR PCR Assay is the first
PCR-based EGFR assay for the use of lung cancer targeted drugs
approved by the SFDA.
"We plan to offer more products on our PCR platform to our top
tier hospital customers served by our direct sales network,"
commented Mr. Xiaodong Wu, Chairman
and Chief Executive Officer of the Company. "As of today, the
Company offers a comprehensive portfolio of molecular diagnostic
products including FISH probes, SPR-based DNA chips and PCR-based
assays. We believe we can further expand these three technology
platforms by offering more products on each platform. In addition,
we will leverage our direct sales network, which covers over 400
top tier hospitals in China, to
promote our new products which have important clinical benefits and
good market potential."
Lung cancer is one of the most common cancers in the world and
it is the leading cause of cancer death in China. It is estimated that more than 500,000
new lung cancer cases were diagnosed each year in China and the incidence rate of lung cancer is
expected to continue to increase. According to publications in
medical journals, EGFR abnormalities have been found in
approximately 85% of NSCLC patients responsive to Iressa and
Tarceva, two commonly used drugs for the treatment of patients with
NSCLC.
About China Medical Technologies, Inc.
China Medical Technologies, Inc. is a leading China-based advanced IVD company using
molecular diagnostic technologies including Fluorescent in situ
Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an
immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay
(ECLIA), to develop, manufacture and distribute diagnostic products
used for the detection of various cancers, diseases and disorders
as well as companion diagnostic tests for targeted cancer drugs.
The Company generates all of its revenues in China through the sale of diagnostic
consumables including FISH probes, SPR-based DNA chips and ECLIA
reagent kits to hospitals which are recurring users of the
consumables for their patients. The Company sells FISH probes and
SPR chips to large hospitals through its direct sales force and
ECLIA reagent kits to small and mid-size hospitals through
distributors. For more information, please visit
http://www.chinameditech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute "forward-looking" statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar
statements. Such statements involve certain risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Further information regarding these
and other risks is included in the Company's filings with the U.S.
Securities and Exchange Commission, including its annual report on
Form 20-F. The Company does not undertake any obligation to update
any forward-looking statement as a result of new information,
future events or otherwise, except as required under applicable
law.
Contact
|
|
|
|
Winnie Yam
|
|
Tel: 852-2511-9808
|
|
Email: IR@chinameditech.com
|
|
|
SOURCE China Medical Technologies, Inc.